Cuu Long Pharmaceutical JSC banner
C

Cuu Long Pharmaceutical JSC
VN:DCL

Watchlist Manager
Cuu Long Pharmaceutical JSC
VN:DCL
Watchlist
Price: 37 150 VND -6.89% Market Closed
Market Cap: ₫2.7T

Multiples-Based Value

The Multiples-Based Value of one DCL stock under the Base Case scenario is hidden VND. Compared to the current market price of 37 150 VND, Cuu Long Pharmaceutical JSC is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DCL Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

DCL Competitors Multiples
Cuu Long Pharmaceutical JSC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Cuu Long Pharmaceutical JSC
VN:DCL
2.7T VND 2.1 139 28.2 53.9
US
Eli Lilly and Co
NYSE:LLY
855.1B USD 13.1 41.4 28 29.9
US
Johnson & Johnson
NYSE:JNJ
574.7B USD 6 27.3 17.5 22.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.6 11.6 13.1
UK
AstraZeneca PLC
LSE:AZN
229B GBP 5.1 29.6 16.4 23
US
Merck & Co Inc
NYSE:MRK
291.8B USD 4.5 16 9.9 12.1
CH
Novartis AG
SIX:NOVN
228.1B CHF 5 20.2 12.5 16.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.8 11.4 8.4 9.8
US
Pfizer Inc
NYSE:PFE
154.6B USD 2.5 19.9 7.7 10.2
UK
GSK plc
XETRA:GS71
99.8B EUR 2.7 15.2 8.2 10.2
P/E Multiple
Earnings Growth PEG
VN
C
Cuu Long Pharmaceutical JSC
VN:DCL
Average P/E: 34
139
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.4
31%
1.3
US
Johnson & Johnson
NYSE:JNJ
27.3
8%
3.4
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.6
25%
1.2
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
CH
Novartis AG
SIX:NOVN
20.2
14%
1.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.9
22%
0.9
UK
GSK plc
XETRA:GS71
15.2
14%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
C
Cuu Long Pharmaceutical JSC
VN:DCL
Average EV/EBITDA: 48.7
28.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28
21%
1.3
US
Johnson & Johnson
NYSE:JNJ
17.5
8%
2.2
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.4
12%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
4%
2.5
CH
Novartis AG
SIX:NOVN
12.5
5%
2.5
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.4
2%
4.2
US
Pfizer Inc
NYSE:PFE
7.7
-8%
N/A
UK
GSK plc
XETRA:GS71
8.2
3%
2.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
C
Cuu Long Pharmaceutical JSC
VN:DCL
Average EV/EBIT: 106.4
53.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.9
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
22.4
13%
1.7
CH
Roche Holding AG
SIX:ROG
13.1
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
CH
Novartis AG
SIX:NOVN
16.1
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
2%
4.9
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
UK
GSK plc
XETRA:GS71
10.2
5%
2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett